UAE - Mubasher: Mubadala Investment Company and Novo Holdings will acquire 11.48 million shares in Germany-headquartered Evotec SE with a total value of EUR 250 million, as part of Evotec's plan to raise its capital.
The UAE's Mubadala will invest EUR 200 million to own around 5.6% of the outstanding shares of Evotec, a drug discovery and development company, according to a press release on Tuesday.
Meanwhile, Evotec’s existing shareholder Novo Holdings will increase its ownership in the company to nearly 11% of outstanding shares in exchange for EUR 50 million.
Evotec’s shares will be issued at a price of EUR 21.78 per share.
After recording the capital increase in the commercial register, Evotec’s share capital will rise to EUR 163.38 million or 163.38 million ordinary bearer shares.
The CEO of Evotec, Werner Lanthaler, commented: "This investment allows us to further accelerate our strategy to create the world-leading “R&D Autobahn to Cures” from discovery to commercial manufacturing.”
The Head of Pharma and Medtech at Mubadala Investment Company, Camilla Macapili Languille, said: "We will work with the company and its shareholders to support Evotec’s strategic growth both through this investment and our extensive institutional network."
